Li Ding, Ph.D.

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Foltz SM, Li Y, Yao L, et al. (2024) Somatic mutation phasing and haplotype extension using linked-reads in multiple myeloma. Biorxiv : the Preprint Server For Biology
Liu Q, Zhang J, Guo C, et al. (2024) Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 187: 184-203.e28
Wu Y, Chen S, Yang X, et al. (2023) Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Research. 83: 4161-4178
Iglesia MD, Jayasinghe RG, Chen S, et al. (2023) Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages. Biorxiv : the Preprint Server For Biology
Terekhanova NV, Karpova A, Liang WW, et al. (2023) Epigenetic regulation during cancer transitions across 11 tumour types. Nature
Liang WW, Lu RJ, Jayasinghe RG, et al. (2023) Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. Cancer Cell
Geffen Y, Anand S, Akiyama Y, et al. (2023) Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell
Li Y, Porta-Pardo E, Tokheim C, et al. (2023) Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell
Li Y, Dou Y, Da Veiga Leprevost F, et al. (2023) Proteogenomic data and resources for pan-cancer analysis. Cancer Cell. 41: 1397-1406
Wu Y, Terekhanova NV, Caravan W, et al. (2023) Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. Nature Communications. 14: 2817